Clinical trial • Cardiology

Clinical trial in Transthyretin cardiac amyloidosis

Clinical trial for Transthyretin cardiac amyloidosis. 104 participants.

Overview

Trial Therapeutic Area
Cardiology
Trial Disease
Transthyretin cardiac amyloidosis

Key dates

Initial CTIS Submission Date
06-12-2024
First CTIS Authorization Date
27-05-2025

Trial design

Clinical trial across 3 sites in Italy.

Target Sample Size
104

Eligibility

Recruits 104 Vulnerable population not selected; no special consent or assent handling described..

Vulnerable Population
Vulnerable population not selected; no special consent or assent handling described.

Recruitment

Planned Sample Size
104
Recruitment Window Months
24

Geography

Total Number Of Sites
3
Total Number Of Participants
104

Italy

Earliest CTIS Part Ii Submission Date
30-10-2024
Latest Decision Or Authorization Date
27-05-2025
Processing Time Days
209
Number Of Sites
3
Number Of Participants
104

Sites

Site Name
Azienda Ospedaliera Universitaria Careggi
Department Name
Terapia Cardiaca Intensiva
Principal Investigator Name
Francesco Cappelli
Principal Investigator Email
f.cappelli@unifi.it
Contact Person Name
Francesco Cappelli
Contact Person Email
f.cappelli@unifi.it
Site Name
Università Sapienza, Azienda Ospedaliera Sant’Andrea
Department Name
UOC Cardiologia
Principal Investigator Name
Beatrice Musumeci
Principal Investigator Email
beatrice.musumeci@uniroma1.it
Contact Person Name
Beatrice Musumeci
Contact Person Email
beatrice.musumeci@uniroma1.it
Site Name
IRCSS Ospedale Policlinico San Martino
Department Name
CardioToraco Vascolare (DICATOV)
Principal Investigator Name
Marco Canepa
Principal Investigator Email
marco.canepa@unige.it
Contact Person Name
Marco Canepa
Contact Person Email
marco.canepa@unige.it

Sponsor

Primary sponsor

Full Name
Universita' Degli Studi Di Genova
Organisation Type
Educational Institution
Country Of Registered Address
Italy

Related trials

Other published trials that may interest you.